孟鲁司特钠与西替利嗪联合布地奈德治疗儿童咳嗽变异性哮喘临床效果、肺功能及安全性  

Analysis of the Clinical Effects,Pulmonary Function and Safety of Montelukast Sodium plus Cetirizine Combined with Budesonide in Children with Cough Variant Asthma

作　　者：丁臻博[1] 鲁萍[1] 黄永坤[1] 赵亚玲[1] 罗艳[1] 段晶[1] DING Zhen-bo;LU Ping;HUANG Yong-kun;ZHAO Ya-ling;LUO Yan;DUAN Jing(Dept.of Pediatrics,The 1st Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)

机构地区：[1]昆明医科大学第一附属医院儿科,云南昆明650032

出　　处：《昆明医科大学学报》2020年第3期86-90,共5页Journal of Kunming Medical University

基　　金：云南省医疗卫生单位内设研究机构项目(2017NS061)。

摘　　要：目的分析应用孟鲁司特与西替利嗪联合布地奈德治疗小儿咳嗽变异哮喘效果、安全性及肺功能情况。方法选择2018年1月至2019年1月昆明医科大学第一附属医院儿科收治的符合纳入标准的60例咳嗽变异性哮喘患儿,按随机数表分为两组,对照组30例,给予吸入布地奈德等常规治疗,研究组30例,在对照组基础上加用孟鲁司特钠与西替利嗪治疗,对两组患儿的临床效果、肺功能及安全性进行对比。结果研究组患儿总有效率93.33%,明显高于对照组73.33%(P<0.05);研究组治疗后FEV1pred(89.00±5.27)%、FEV1/FVC(89.24±6.28)%与PEFpred(86.17±5.22)%指标高于对照组FEV1pred(84.00±5.26)%、FEV1/FVC(85.96±6.17)%与PEFpred(82.86±4.98)%,差异具有统计学意义(P<0.05);研究组不良反应率6.67%低于对照组26.67%(P<0.05)。结论使用在布地奈德基础上应用孟鲁司特钠联合西替利嗪治疗小儿咳嗽变异性哮喘,可改善患儿肺功能,减少不良反应发生,安全性高,值得临床推广和使用。Objective To analyze the clinical effects,safety and pulmonary function of montelukast sodium plus cetirizine combined with budesonide in the treatment of cough variant asthma in children.Methods A total of 60 children with cough variant asthma admitted into the First Affiliated Hospital of Kunming Medical University from January 2018 to January 2019 were divided into two groups according to random number table:30 in the control group being given budesonide and 30 in the experimental group being treated with montelukast sodium plus cetirizine combined with budesonide.The clinical effects,pulmonary function and safety between the two groups were compared.Results The total effective rate of the experimental group was 93.33%,which was significantly higher than that of the control group(73.33%,P<0.05).In the experimental group,FEV1 pred,FEV1/FVC and PEF pred were(89.00±5.27)%,(89.24±6.28)and(86.17±5.22)%,respectively,which were significantly higher than those in the control group,(84.00±5.26)%,(85.96±6.17)%and(82.86±4.98),respectively(P<0.05).The adverse reaction rate of the experimental group was 6.67%,which was significantly lower than that of the control group(26.67%,P<0.05).Conclusions The use of montelukast sodium plus cetirizine combined with budesonide in the treatment of cough variant asthma in children can improve pulmonary function,reduce the occurrence of adverse reactions,and increase the level of safety,which is worthy of clinical promotion and use.

关 键 词：孟鲁司特钠 西替利嗪 布地奈德 小儿咳嗽变异性哮喘 临床效果 肺功能 安全性 

分 类 号：R725.6[医药卫生—儿科]